Showing posts with label Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults. Show all posts
Showing posts with label Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults. Show all posts
Thursday, July 21, 2022

FDA Approves Amvuttra (vutrisiran) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults

›
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administrat...